Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs)
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science
Link
https://link.springer.com/content/pdf/10.1208/s12248-022-00741-x.pdf
Reference58 articles.
1. Lundin KE, Gissberg O, CIE S. Oligonucleotide therapies: the past and the present. Hum Gene Ther. 2015;26:475–85.
2. Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Pharmacology of antisense drugs [Internet]. Vol. 57, Annual Review of Pharmacology and Toxicology. Annual Reviews; 2017 [cited 2021 Nov 1]. p. 81–105. Available from: https://www.annualreviews.org/doi/abs/10.1146/annurev-pharmtox-010716-104846
3. Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther. 2017;25:1069–75.
4. Bennett CF. Therapeutic antisense oligonucleotides are coming of age [Internet]. Vol. 70, Annual Review of Medicine. Annual Reviews; 2019 [cited 2021 Nov 1]. p. 307–21. Available from: https://www.annualreviews.org/doi/abs/10.1146/annurev-med-041217-010829
5. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:537–50.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety;The AAPS Journal;2024-04-03
2. A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery;Journal of Materials Chemistry B;2024
3. Immunogenicity and Immune-Related Adverse Drug Reactions;Reference Module in Biomedical Sciences;2024
4. OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides;Nucleic Acid Therapeutics;2023-10-01
5. 2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach);Bioanalysis;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3